CA2983668C - Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors - Google Patents
Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors Download PDFInfo
- Publication number
- CA2983668C CA2983668C CA2983668A CA2983668A CA2983668C CA 2983668 C CA2983668 C CA 2983668C CA 2983668 A CA2983668 A CA 2983668A CA 2983668 A CA2983668 A CA 2983668A CA 2983668 C CA2983668 C CA 2983668C
- Authority
- CA
- Canada
- Prior art keywords
- mmol
- pyrazol
- reaction mixture
- methy1
- et0ac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
- C07D231/50—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562156424P | 2015-05-04 | 2015-05-04 | |
| US62/156424 | 2015-05-04 | ||
| PCT/EP2016/059848 WO2016177703A1 (en) | 2015-05-04 | 2016-05-03 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2983668A1 CA2983668A1 (en) | 2016-11-10 |
| CA2983668C true CA2983668C (en) | 2023-06-27 |
Family
ID=55910253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2983668A Active CA2983668C (en) | 2015-05-04 | 2016-05-03 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors |
Country Status (38)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR104512A1 (es) | 2015-05-04 | 2017-07-26 | Astrazeneca Ab | Compuestos de pirazol inhibidores de proteĆna activadora de 5-lipoxigenasa (flap) |
| CN109890385B (zh) * | 2016-10-28 | 2022-08-02 | éæęÆå©åŗ·(ēå ø)ęéå ¬åø | (1r,2r)-2-[4-(3-ē²åŗ-1h-å”å-5-åŗ)čÆē²é °åŗ]-n-(4-ę°§ä»£-4,5,6,7-åę°¢å”å并[1,5-a]å”åŖ-3-åŗ)ēÆå·±ē·ē²é °čŗēē»ę¶å½¢å¼ |
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| CN110169969B (zh) * | 2019-06-28 | 2022-05-27 | åäŗ¬å»ē§å¤§å¦ | Mk571åØå¶å¤é¢é²åę²»ēåæčē čÆē©äøåŗēØ |
| CN111084775A (zh) * | 2020-02-17 | 2020-05-01 | ē”äø¹ę±å»å¦é¢ | äøē§ēØäŗę²»ēē«ē«ēčÆē©ē»åē© |
| CN111419800B (zh) * | 2020-04-23 | 2021-03-19 | ęø©å·å»ē§å¤§å¦éå±ē¬¬äŗå»é¢ćęø©å·å»ē§å¤§å¦éå±č²č±åæē«„å»é¢ | ēØäŗę²»ēēŗ¢ęē¼ē®ēčÆē©å¶ååå ¶å¶å¤ę¹ę³ |
| CN111643498B (zh) * | 2020-07-20 | 2021-05-07 | é»é¾ę±äøå»čÆå¤§å¦ | äøē§ę²»ēč¾ē»ē³ēčÆē©ē»åē©åå ¶ēØé |
| CN111714499B (zh) * | 2020-07-27 | 2021-05-11 | é»é¾ę±äøå»čÆå¤§å¦ | äøē§ēØäŗę²»ēå¤ååµå·¢ē»¼åå¾ēčÆē©ē»åē© |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP9400632A0 (en) | 1993-04-29 | 1995-10-07 | Zeneca Ltd | Ether derivatives. |
| US5773422A (en) | 1996-01-29 | 1998-06-30 | Komer; Gene | Avermectin formulation |
| EP1670804A2 (en) * | 2003-09-10 | 2006-06-21 | GPC Biotech AG | Heterobicyclic compounds as pharmaceutically active agents |
| GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| TW200815351A (en) * | 2006-05-02 | 2008-04-01 | Astrazeneca Ab | Novel compounds |
| JP2010518025A (ja) | 2007-02-05 | 2010-05-27 | ć¢ćć© ćć”ć¼ćć·ć„ć¼ćć£ć«ć«ć¹ļ¼ć¤ć³ć³ć¼ćć¬ć¼ććć | ļ¼āćŖććć·ć²ćć¼ć¼ę“»ę§åćæć³ććÆč³Ŗļ¼ļ½ļ½ļ½ļ½ļ¼ć¤ć³ćććæć¼ćØćć¦ć®éć¤ć³ćć¼ć« |
| GB0702456D0 (en) * | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination |
| CA2684618A1 (en) * | 2007-04-20 | 2008-10-30 | Schering Corporation | Tetrahydropyrido[4,3-d]pyrimidinone derivatives and methods of use thereof |
| US9096546B2 (en) * | 2007-05-10 | 2015-08-04 | Albany Molecular Research, Inc. | Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| WO2009045700A2 (en) | 2007-10-05 | 2009-04-09 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| AR104512A1 (es) * | 2015-05-04 | 2017-07-26 | Astrazeneca Ab | Compuestos de pirazol inhibidores de proteĆna activadora de 5-lipoxigenasa (flap) |
-
2016
- 2016-05-03 AR ARP160101257A patent/AR104512A1/es active IP Right Grant
- 2016-05-03 PL PL19199606T patent/PL3670499T3/pl unknown
- 2016-05-03 HU HUE19199606A patent/HUE056875T2/hu unknown
- 2016-05-03 US US15/571,291 patent/US10183947B2/en active Active
- 2016-05-03 RS RS20191604A patent/RS59671B1/sr unknown
- 2016-05-03 HU HUE16720116A patent/HUE047445T2/hu unknown
- 2016-05-03 EA EA201792341A patent/EA032221B1/ru not_active IP Right Cessation
- 2016-05-03 PE PE2017002308A patent/PE20180247A1/es unknown
- 2016-05-03 EP EP16720116.9A patent/EP3292105B1/en active Active
- 2016-05-03 JP JP2017555792A patent/JP6564062B2/ja active Active
- 2016-05-03 SG SG11201708558RA patent/SG11201708558RA/en unknown
- 2016-05-03 HR HRP20192172TT patent/HRP20192172T1/hr unknown
- 2016-05-03 SM SM20210722T patent/SMT202100722T1/it unknown
- 2016-05-03 CR CR20170513A patent/CR20170513A/es unknown
- 2016-05-03 SM SM20190691T patent/SMT201900691T1/it unknown
- 2016-05-03 SI SI201631428T patent/SI3670499T1/sl unknown
- 2016-05-03 MY MYPI2017704101A patent/MY186647A/en unknown
- 2016-05-03 TW TW105113757A patent/TWI718146B/zh active
- 2016-05-03 SI SI201630537T patent/SI3292105T1/sl unknown
- 2016-05-03 ES ES19199606T patent/ES2902139T3/es active Active
- 2016-05-03 RS RS20211559A patent/RS62729B1/sr unknown
- 2016-05-03 PL PL16720116T patent/PL3292105T3/pl unknown
- 2016-05-03 ES ES16720116T patent/ES2760466T3/es active Active
- 2016-05-03 PT PT167201169T patent/PT3292105T/pt unknown
- 2016-05-03 PT PT191996065T patent/PT3670499T/pt unknown
- 2016-05-03 KR KR1020177034920A patent/KR102623474B1/ko active Active
- 2016-05-03 AU AU2016258874A patent/AU2016258874B2/en active Active
- 2016-05-03 EP EP19199606.5A patent/EP3670499B1/en active Active
- 2016-05-03 MX MX2017013571A patent/MX372755B/es active IP Right Grant
- 2016-05-03 DK DK16720116T patent/DK3292105T3/da active
- 2016-05-03 LT LTEP19199606.5T patent/LT3670499T/lt unknown
- 2016-05-03 WO PCT/EP2016/059848 patent/WO2016177703A1/en not_active Ceased
- 2016-05-03 CA CA2983668A patent/CA2983668C/en active Active
- 2016-05-03 HR HRP20211993TT patent/HRP20211993T1/hr unknown
- 2016-05-03 ME MEP-2019-358A patent/ME03663B/me unknown
- 2016-05-03 TN TNP/2017/000458A patent/TN2017000458A1/en unknown
- 2016-05-03 BR BR112017022757-6A patent/BR112017022757B1/pt active IP Right Grant
- 2016-05-03 CN CN201680029387.0A patent/CN107646036B/zh active Active
- 2016-05-03 DK DK19199606.5T patent/DK3670499T3/da active
-
2017
- 2017-10-16 IL IL255069A patent/IL255069B/en active IP Right Grant
- 2017-10-18 GT GT201700220A patent/GT201700220A/es unknown
- 2017-10-19 CL CL2017002660A patent/CL2017002660A1/es unknown
- 2017-10-20 DO DO2017000244A patent/DOP2017000244A/es unknown
- 2017-10-20 SV SV2017005549A patent/SV2017005549A/es unknown
- 2017-11-09 CO CONC2017/0011506A patent/CO2017011506A2/es unknown
- 2017-11-21 PH PH12017502112A patent/PH12017502112B1/en unknown
- 2017-12-01 ZA ZA2017/08189A patent/ZA201708189B/en unknown
-
2018
- 2018-11-20 US US16/196,217 patent/US10508119B2/en active Active
-
2019
- 2019-10-30 US US16/668,743 patent/US11001589B2/en active Active
- 2019-12-03 CY CY20191101268T patent/CY1122689T1/el unknown
-
2021
- 2021-04-22 US US17/237,656 patent/US11691978B2/en active Active
- 2021-12-23 CY CY20211101130T patent/CY1125179T1/el unknown
-
2023
- 2023-02-27 US US18/174,832 patent/US12024523B2/en active Active
-
2024
- 2024-05-21 US US18/670,264 patent/US20240317767A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2983668C (en) | Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors | |
| CA2770320A1 (en) | Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof | |
| WO2014028589A2 (en) | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| AU2014291711A1 (en) | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core | |
| AU2024202860A1 (en) | Metalloenzyme inhibitor compounds | |
| EP3224255A1 (en) | N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | |
| AU2010328049A1 (en) | Azocyclic inhibitors of fatty acid amide hydrolase | |
| US20110312941A1 (en) | 1,4-disubstituted piperidines as vasopressin receptor via antagonists | |
| WO2018109642A1 (en) | N-aryl pyrazoles as nrf2 regulators | |
| HK1245255B (en) | Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors | |
| NZ737672B2 (en) | Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors | |
| CA3022793A1 (en) | Aromatic sulfonamide derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210503 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250422 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250422 |